CN114634904B - 高纯度胰腺祖细胞的产生方法 - Google Patents
高纯度胰腺祖细胞的产生方法 Download PDFInfo
- Publication number
- CN114634904B CN114634904B CN202210541011.5A CN202210541011A CN114634904B CN 114634904 B CN114634904 B CN 114634904B CN 202210541011 A CN202210541011 A CN 202210541011A CN 114634904 B CN114634904 B CN 114634904B
- Authority
- CN
- China
- Prior art keywords
- culture medium
- differentiation
- day
- days
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 36
- 238000004519 manufacturing process Methods 0.000 title abstract description 3
- 210000004027 cell Anatomy 0.000 claims abstract description 96
- 230000004069 differentiation Effects 0.000 claims abstract description 60
- 238000000034 method Methods 0.000 claims abstract description 34
- 230000006698 induction Effects 0.000 claims abstract description 31
- 210000001900 endoderm Anatomy 0.000 claims abstract description 20
- 238000010790 dilution Methods 0.000 claims abstract description 11
- 239000012895 dilution Substances 0.000 claims abstract description 11
- 238000011081 inoculation Methods 0.000 claims abstract description 8
- 239000001963 growth medium Substances 0.000 claims description 44
- 239000000654 additive Substances 0.000 claims description 16
- 230000000996 additive effect Effects 0.000 claims description 16
- 239000002609 medium Substances 0.000 claims description 16
- 108010082117 matrigel Proteins 0.000 claims description 15
- CUKSFECWKQBVED-INIZCTEOSA-N Decursin Chemical compound C1=CC(=O)OC2=C1C=C1C[C@H](OC(=O)C=C(C)C)C(C)(C)OC1=C2 CUKSFECWKQBVED-INIZCTEOSA-N 0.000 claims description 12
- CUKSFECWKQBVED-UHFFFAOYSA-N Grandivittin Natural products C1=CC(=O)OC2=C1C=C1CC(OC(=O)C=C(C)C)C(C)(C)OC1=C2 CUKSFECWKQBVED-UHFFFAOYSA-N 0.000 claims description 11
- JXZWWIMXTVJNSF-UHFFFAOYSA-N decursin Natural products CC(=CC(=O)OC1Oc2cc3OC(=O)C=Cc3cc2CC1(C)C)C JXZWWIMXTVJNSF-UHFFFAOYSA-N 0.000 claims description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 8
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 8
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 claims description 6
- 239000006285 cell suspension Substances 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 210000002438 upper gastrointestinal tract Anatomy 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 150000004665 fatty acids Chemical class 0.000 claims description 5
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 claims description 4
- 238000004113 cell culture Methods 0.000 claims description 4
- 210000001647 gastrula Anatomy 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 239000011435 rock Substances 0.000 claims description 2
- 102100041030 Pancreas/duodenum homeobox protein 1 Human genes 0.000 abstract description 19
- 101710183548 Pyridoxal 5'-phosphate synthase subunit PdxS Proteins 0.000 abstract description 19
- 102100028096 Homeobox protein Nkx-6.2 Human genes 0.000 abstract description 18
- 101000578254 Homo sapiens Homeobox protein Nkx-6.1 Proteins 0.000 abstract description 18
- 101000578258 Homo sapiens Homeobox protein Nkx-6.2 Proteins 0.000 abstract description 18
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 abstract description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 abstract description 2
- 210000002744 extracellular matrix Anatomy 0.000 abstract description 2
- 238000010166 immunofluorescence Methods 0.000 description 15
- 230000000052 comparative effect Effects 0.000 description 13
- 238000010186 staining Methods 0.000 description 13
- 238000003556 assay Methods 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 5
- 238000000116 DAPI staining Methods 0.000 description 5
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 210000004940 nucleus Anatomy 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102100029284 Hepatocyte nuclear factor 3-beta Human genes 0.000 description 1
- 101001062347 Homo sapiens Hepatocyte nuclear factor 3-beta Proteins 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 101100310648 Mus musculus Sox17 gene Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008143 early embryonic development Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002304 esc Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000003577 pancreatic endocrine progenitor Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
- C12N5/0678—Stem cells; Progenitor cells; Precursor cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
试剂名称 | 公司(货号) |
mTeSR1 | STEMCELL (85850) |
MCDB131 | Gibco (10372019) |
GlutaMAX Supplement | Gibco (35050061) |
B27 | Gibco (17504044) |
Y-27632 | R&D (1254) |
CHIR99021 | R&D (4423) |
rhActA | R&D (338-AC) |
rhFGF7 | R&D (251-KG) |
rhEGF | R&D (236-EG) |
Matrigel(GFR) | Corning (356230) |
TrypLE™ Express 酶 (1X),无酚红 | Gibco (12604021) |
Glucose | Sigma (D9434) |
NaHCO<sub>3</sub> | Sigma (S5761) |
BSA | Proliant (68700) |
Vc | Tocris (4055) |
P/S | Gibco (10378016) |
RA | Tocris (0695) |
SANT1 | Tocris(1974) |
Decursin | MCE (HY-18981 ) |
ML347 | Tocris (4945) |
NIC | Tocris (4106) |
hPSC | Wisconsin Cell Research Institute (ES01) |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210541011.5A CN114634904B (zh) | 2022-05-17 | 2022-05-17 | 高纯度胰腺祖细胞的产生方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210541011.5A CN114634904B (zh) | 2022-05-17 | 2022-05-17 | 高纯度胰腺祖细胞的产生方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114634904A CN114634904A (zh) | 2022-06-17 |
CN114634904B true CN114634904B (zh) | 2022-09-13 |
Family
ID=81952747
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210541011.5A Active CN114634904B (zh) | 2022-05-17 | 2022-05-17 | 高纯度胰腺祖细胞的产生方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114634904B (zh) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2844739T3 (pl) * | 2012-04-30 | 2019-12-31 | University Health Network | SPOSOBY I KOMPOZYCJE DO WYTWARZANIA PROGENITORÓW TRZUSTKI I FUNKCJONALNYCH KOMÓREK BETA Z hPSC |
AU2013271581B2 (en) * | 2012-06-08 | 2018-08-09 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells into pancreatic endocrine cells |
CN112251396B (zh) * | 2020-10-09 | 2022-08-16 | 北京呈诺医学科技有限公司 | 培养基及其应用与诱导性多能干细胞向胰岛分化的方法 |
CN113046299B (zh) * | 2021-03-19 | 2024-06-28 | 上海爱萨尔生物科技有限公司 | 一种诱导多能干细胞定向分化制备胰岛β细胞的添加剂 |
-
2022
- 2022-05-17 CN CN202210541011.5A patent/CN114634904B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN114634904A (zh) | 2022-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2007210580B2 (en) | A method for purifying cardiomyocytes or programmed cardiomyocytes derived from stem cells or fetuses | |
CN113046318B (zh) | 一种诱导多能干细胞向造血前体细胞分化的培养基以及方法 | |
CN108384746B (zh) | 一种诱导性多能干细胞向成熟内皮细胞高效分化的方法 | |
CN100465268C (zh) | 人胚胎干细胞的培养方法及其专用培养基 | |
WO2021254296A1 (zh) | 一种生物活性物质组合物、包含所述组合物的无血清培养基及其用途 | |
WO2015042356A1 (en) | Chemically defined culture medium for stem cell maintenance and differentiation | |
CN110747163B (zh) | 一种提高人脂肪间充质干细胞成脂分化的方法及其专用培养基 | |
CN110607277B (zh) | 一种人类多能干细胞分化巨噬细胞的方法 | |
CN112680417A (zh) | 一种卵巢癌类器官培养基及培养方法 | |
CN113249310A (zh) | 一种拓展性多能干细胞诱导分化为心肌细胞的方法及应用 | |
CN114703123B (zh) | 一种通过调节NGN3表达促进iPSC向胰岛细胞分化的方法 | |
CN113388572B (zh) | 高效人多能干细胞体外诱导分化为多谱系小肠类器官方法 | |
CN114634904B (zh) | 高纯度胰腺祖细胞的产生方法 | |
US20160340652A1 (en) | Culture medium for stem cell differentiation | |
CN113528441A (zh) | 快速高效的临床级色素上皮细胞诱导方法、试剂盒及应用 | |
CN112522187A (zh) | 一种人软骨细胞培养基及其应用 | |
JP2015231365A (ja) | 内耳細胞誘導方法 | |
WO2022213704A1 (zh) | 一种高迁徙间充质干细胞及其制备方法和应用 | |
CN112592883B (zh) | 一种小鼠胰腺类器官培养基及其应用 | |
CN110938584B (zh) | 一种人胚胎干细胞向内皮细胞诱导分化的方法 | |
CN113755433A (zh) | 一种滑膜间充质干细胞的悬浮液及其制备方法 | |
CN113106066A (zh) | 一种肉瘤细胞培养基以及采用该培养基体外生产Matrigel原液的方法 | |
CN111876373A (zh) | 化学成分明确的人气道上皮细胞无血清培养基及其应用 | |
CN110564688B (zh) | 一种无血清培养角膜缘基质干细胞并于体外诱导成球和诱导分化的方法 | |
CN113832097B (zh) | 组合物及含有其的无血清、无饲养层干细胞培养基及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Ge Xiaohu Inventor after: Wu Di Inventor after: Wang Sisi Inventor after: Luo Xiaoqin Inventor after: Li Huifang Inventor before: Ge Xiaohu Inventor before: Wang Sisi Inventor before: Wu Di Inventor before: Luo Xiaoqin Inventor before: Li Huifang |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20220819 Address after: Room 906, Building 22, Green Valley Health Industrial Park, No. 59, Kangtai Avenue, Binhai Science and Technology Park, High-tech Zone, Binhai New District, Tianjin 300452 Applicant after: Tianjin exosome Technology Co.,Ltd. Address before: 300452 building 20, Green Valley Health Industrial Park, No. 59, Kangtai Avenue, Binhai Science Park, Binhai high tech Zone, Binhai New Area, Tianjin Applicant before: Tianjiu regenerative medicine (Tianjin) Technology Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240130 Address after: Room 915-30, 9th Floor, Zhongxin Ecological Building, No. 2 Keying Road, Suzhou Industrial Park, Suzhou City, Jiangsu Province, 215000 Patentee after: Qijia Technology (Suzhou) Co.,Ltd. Country or region after: China Address before: Room 906, Building 22, Green Valley Health Industrial Park, No. 59, Kangtai Avenue, Binhai Science and Technology Park, High-tech Zone, Binhai New District, Tianjin 300452 Patentee before: Tianjin exosome Technology Co.,Ltd. Country or region before: China |